The biocompatibles’ drug-eluting stents

Handbook of Coronary Stents, Fourth Edition

Volumn , Issue , 2001, Pages 300-310

  Rothman, Martin T ^a   Lewis, Andrew L ^b  

^a LONDON CHEST HOSPITAL   (United Kingdom)

^b BIOCOMPATIBLES UK LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33644755401     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (8)

1. Edelman E, Rogers C. Pathobiologic responses to stenting. Am J Cardiol 1998; 81: 4E–6E.
2. Lewis AL. Phosphorylcholine-based polymers and their use in the prevention of biofouling. Coll Surf B: Biointerfaces 2000; 18: 261–75.
3. Whelan DM, van der Giessen WJ, Krabbendam SC, et al. Biocompatibility of phosphorylcholine coated stents in normal porcine coronary arteries. Heart 2000; 83: 338–45.
4. Lewis AL, Tolhurst LA, Stratford PW. Analysis of a phosphorylcholine-based polymer coating on a coronary stent pre-and post-implantation. Biomaterials (in press).
5. Tang Y. Swelling of biocompatible polymer films. PhD Thesis, The University of Surrey, 2001.
6. Lewis AL, Vick TA, Collias ACM et al. Phosphorylcholine-based polymer coatings for stent drug delivery. J Mater Sci, Mater Medicine (in press).
7. Armstrong J, Gunn J, Holt CM et al. Local angiopeptin delivery from coronary stents in porcine coronary arteries. Eur Heart J 1999; 20(Abst 366): 1929.
8. De Scheerder I, Huang Y. Anti-inflammatory approach to restenosis. In: Rothman MT (Ed), Restenosis: Multiple Strategies for Stent Drug Delivery (The Restenosis Matrix), ReMedica, 2001.